DEVELOPMENT CONCEPT - NOT FOR SALE

LONGEVITY CORE

Public development concept for a once-daily 10 g high-barrier sachet.

Prepared by	Stasinos Sikalias, Pharmacist | CEO & R&D Manager
Audience	Potential development, distribution and commercial partners
Document date	07 September 2026
Version	1.0

Educational and business-development publication. It does not replace product-specific development, risk assessment, current official guidance, regulatory review, validated methods, stability data or professional clinical judgement.

ΕΛΛΗΝΙΚΗ ΕΚΔΟΣΗ

Concept status

Αναπτυξιακή πρόταση - δεν αποτελεί τελικό εμπορικό προϊόν, εγκεκριμένη ετικέτα ή προσφορά προς πώληση. Η τελική σύνθεση, πρώτες ύλες, γεύση, ισχυρισμοί, shelf life και artwork απαιτούν supplier qualification, laboratory/pilot work, analytical strategy, stability και regulatory review.

Working composition per sachet

Η τρέχουσα working architecture περιλαμβάνει creatine monohydrate 3.000 mg, glycine 3.000 mg, trimethylglycine (TMG) 1.500 mg, magnesium citrate 750 mg με στόχο παροχής 120 mg μαγνησίου, vitamin C 100 mg και vitamin D/B-vitamin premixes που θα οριστικοποιηθούν βάσει του ακριβούς grade και του ευρωπαϊκού label strategy.

Product format

Μία ημερήσια μονοδόση σε high-barrier sachet, 30 sachets ανά συσκευασία. Ο στόχος είναι πλήρεις, διαφανείς δόσεις σε πρακτική powder format και παραγωγή/συσκευασία με ελεγχόμενη υγρασία για moisture-sensitive components.

Positioning principles

Το consumer communication πρέπει να στηρίζεται μόνο σε επιτρεπόμενους ισχυρισμούς για τα nutrients που πληρούν τις προϋποθέσεις χρήσης. Η creatine μπορεί να αποτελέσει βασικό performance/healthy-ageing axis μόνο με το ακριβές ευρωπαϊκό authorised wording και conditions of use. Δεν χρησιμοποιούνται θεραπευτικοί ή “anti-ageing” ισχυρισμοί.

Development gates

Raw-material and premix qualification, flavour/solubility work, bulk density and sachet fill verification, moisture and oxygen risk assessment, analytical methods, pilot batch, packaging compatibility, stability, label/legal review and commercial feasibility.

ENGLISH VERSION

Concept status

Development concept - not a final commercial product, approved label or offer for sale. Final formula, grades, flavour, claims, shelf life and artwork require supplier qualification, laboratory/pilot work, analytical strategy, stability and regulatory review.

Working composition per sachet

The current working architecture includes creatine monohydrate 3,000 mg, glycine 3,000 mg, trimethylglycine (TMG) 1,500 mg, magnesium citrate 750 mg targeting 120 mg magnesium, vitamin C 100 mg, and vitamin D/B-vitamin premixes to be finalised against exact grades and the EU label strategy.

Product format

One daily 10 g high-barrier sachet, 30 sachets per pack. The concept uses fully disclosed doses in a practical powder format and controlled-humidity production/packaging for moisture-sensitive components.

Positioning principles

Consumer communication must rely only on permitted claims for nutrients meeting their conditions of use. Creatine can provide a central performance/healthy-ageing axis only with the exact authorised EU wording and conditions. No therapeutic or anti-ageing claims are proposed.

Development gates

Raw-material and premix qualification, flavour/solubility work, bulk-density and fill verification, moisture/oxygen risk assessment, analytical methods, pilot batch, packaging compatibility, stability, legal label review and commercial feasibility.

Selected references and standards

ICH Q8(R2), Pharmaceutical Development, International Council for Harmonisation.

ICH Q9(R1), Quality Risk Management, International Council for Harmonisation.

ICH Q10, Pharmaceutical Quality System, International Council for Harmonisation.

European Commission, EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice.

EU GMP Annex 15, Qualification and Validation.

FIP/WHO, Joint Guidelines on Good Pharmacy Practice: Standards for Quality of Pharmacy Services.